Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein

Nature Communications

Volumn 5, Issue , 2014, Pages

  Yu, Le Xing ^a,b   Yan, Lei ^a,b   Yang, Wen ^a,b   Wu, Fu Quan ^a,b   Ling, Yan ^a,b   Chen, Shu Zhen ^a,b   Tang, Liang ^a,b   Tan, Ye Xiong ^a,b   Cao, Dan ^a,b   Wu, Meng Chao ^a,b   Yan, He Xin ^a,b   Wang, Hong Yang ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Eastern Hepatobiliary Surgery Hospital   (China)

^c Shanghai Institute of Digestive Disease   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; HIGH MOBILITY GROUP B1 PROTEIN; PADGEM PROTEIN; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; TOLL LIKE RECEPTOR 4; ANTITHROMBOCYTIC AGENT; PROTEIN BINDING; TLR4 PROTEIN, MOUSE;

CANCER; EXPERIMENT; GENE EXPRESSION; LIGAND; NEUTRALIZATION; PROTEIN; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER GROWTH; CELL INTERACTION; CELL MIGRATION; CONTROLLED STUDY; DISTANT METASTASIS; EXPERIMENTAL NEOPLASM; HEMATOPOIETIC CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MELANOMA CELL; MELANOMA METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SPLEEN CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; TUMOR PROMOTION; ANIMAL; C57BL MOUSE; CELL COMMUNICATION; DEFICIENCY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; HEMATOPOIESIS; METABOLISM; METASTASIS; PATHOLOGY; THROMBOCYTE; TUMOR CELL LINE;

MUS;

ANIMALS; BLOOD PLATELETS; CARCINOMA, LEWIS LUNG; CELL COMMUNICATION; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOPOIESIS; HMGB1 PROTEIN; MALE; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; NEOPLASM METASTASIS; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; TOLL-LIKE RECEPTOR 4;

EID: 84923381173     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6256     Document Type: Article

References (51)

1. Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006).
2. Weiss, L. Metastatic inefficiency. Adv. Cancer Res. 54, 159-211 (1990).
3. Luzzi, K. J. et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153, 865-873 (1998).
4. Labelle, M. & Hynes, R. O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2, 1091-1099 (2012).
5. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123-134 (2011).
6. Coupland, L. A., Chong, B. H. & Parish, C. R. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 72, 4662-4671 (2012).
7. Gil-Bernabe, A. M., Lucotti, S. & Muschel, R. J. Coagulation and metastasis: what does the experimental literature tell us? Br. J. Haematol. 162, 433-441 (2013).
8. Nieswandt, B., Hafner, M., Echtenacher, B. & Mannel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295-1300 (1999).
9. Rickles, F. R. & Falanga, A. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 102, V215-V224 (2001).
10. Riedl, J., Pabinger, I. & Ay, C. Platelets in cancer and thrombosis. Hamostaseologie 34, 54-62 (2014).
11. Placke, T. et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 72, 440-448 (2012).
12. Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576-590 (2011).
13. Kanzler, H., Barrat, F. J., Hessel, E. M. & Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552-559 (2007).
14. Yu, L. X. et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52, 1322-1333 (2010).
15. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059 (2007).
16. Harmey, J. H. et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J. Cancer 101, 415-422 (2002).
17. Jing, Y. Y. et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 10, 98 (2012).
18. Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162 (2011).
19. Andonegui, G. et al. Platelets express functional Toll-like receptor-4. Blood 106, 2417-2423 (2005).
20. Aslam, R. et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 107, 637-641 (2006).
21. Zhang, G. et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J. Immunol. 182, 7997-8004 (2009).
22. Semple, J. W., Italiano, Jr J. E. & Freedman, J. Platelets and the immune continuum. Nat. Rev. Immunol. 11, 264-274 (2011).
23. Jayachandran, M. et al. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J. Appl. Physiol. (1985) 102, 429-433 (2007).
24. Pearson, H. B. & Pouliot, N. in Metastatic Cancer: Clinical and Biological Perspectives (ed. Jandial, R.) (Landes Bioscience, 2013).
25. Francia, G., Cruz-Munoz, W., Man, S., Xu, P. & Kerbel, R. S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 11, 135-141 (2011).
26. Huang, B. et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009-5014 (2005).
27. Matsunaga, N., Tsuchimori, N., Matsumoto, T. & Ii, M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol. Pharmacol. 79, 34-41 (2011).
28. Sha, T. et al. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur. J. Pharmacol. 571, 231-239 (2007).
29. Jayachandran, M. et al. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J. Appl. Physiol. 102, 429-433 (2007).
30. Andonegui, G. et al. Platelets express functional Toll-like receptor-4. Blood 106, 2417-2423 (2005).
31. Grainger, D. J., Wakefield, L., Bethell, H. W., Farndale, R. W. & Metcalfe, J. C. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat. Med. 1, 932-937 (1995).
32. Assoian, R. K. & Sporn, M. B. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J. Cell Biol. 102, 1217-1223 (1986).
33. Li, Z. et al. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J. Biol. Chem. 278, 30725-30731 (2003).
34. Grundy, M. A., Zhang, T. & Sentman, C. L. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunol. Immunother. 56, 1153-1161 (2007).
35. Ye, Z. et al. Engineered CD8\+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors. Cancer Gene. Ther. 14, 661-675 (2007).
36. Mauti, L. A. et al. Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest. 121, 2794-2807 (2011).
37. Palumbo, J. S. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178-185 (2005).
38. Erpenbeck, L. & Schon, M. P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427-3436 (2010).
39. Camerer, E. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397-401 (2004).
40. Im, J. H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer. Res. 64, 8613-8619 (2004).
41. Boucharaba, A. et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114, 1714-1725 (2004).
42. Zhang, W. et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood 120, 2889-2898 (2012).
43. Patrono, C., Baigent, C., Hirsh, J. & Roth, G. American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 199S-233S (2008).
44. Jennings, L. K. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb. Haemost. 102, 248-257 (2009).
45. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990 (2005).
46. Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002).
47. Li, L. et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54, 1620-1630 (2011).
48. Hossain, M. A. et al. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int. J. Oncol. 40, 1298-1304 (2012).
49. Buergy, D., Wenz, F., Groden, C. & Brockmann, M. A. Tumor-platelet interaction in solid tumors. Int. J. Cancer 130, 2747-2760 (2012).
50. Lin, Y. et al. Gut-derived lipopolysaccharide promotes T-cell-mediated hepatitis in mice through Toll-like receptor 4. Cancer Prev. Res. (Phila) 5, 1090-1102 (2012).
51. Egan, K. et al. Platelet adhesion and degranulation induce pro-survival and proangiogenic signalling in ovarian cancer cells. PLoS ONE 6, e26125 (2011).